BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 10179747)

  • 1. Prognostic factors: classification approaches in patients with lung cancer.
    Stanisavljević D; Jovanović D; Marinković J; Milosavljević M
    Stud Health Technol Inform; 1997; 43 Pt B():652-5. PubMed ID: 10179747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prognosis after complete surgical resection for non-small cell lung cancer based on the staging classification].
    Pfannschmidt J; Muley T; Hoffmann H; Bülzebruck H; Dienemann H
    Dtsch Med Wochenschr; 2006 Nov; 131(47):2643-8. PubMed ID: 17109272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
    Saito T; Hara N; Kitamura Y; Komatsubara S
    Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
    Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
    Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study design considerations in clinical outcome research of lung cancer using microarray analysis.
    Yang P; Sun Z; Aubry MC; Kosari F; Bamlet W; Endo C; Molina JR; Vasmatzis G
    Lung Cancer; 2004 Nov; 46(2):215-26. PubMed ID: 15474670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
    J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic impact of tumor size in resected stage I non-small cell lung cancer: evidence for a two thresholds tumor diameters classification.
    Christian C; Erica S; Morandi U
    Lung Cancer; 2006 Nov; 54(2):185-91. PubMed ID: 16996167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
    Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
    Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of metastasis to the highest mediastinal lymph node in nonsmall cell lung cancer.
    Sakao Y; Miyamoto H; Yamazaki A; Oh T; Fukai R; Shiomi K; Saito Y
    Ann Thorac Surg; 2006 Jan; 81(1):292-7. PubMed ID: 16368383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic N1 non-small cell lung cancer: correlation between pattern of lymphatic spread and prognosis.
    Marra A; Hillejan L; Zaboura G; Fujimoto T; Greschuchna D; Stamatis G
    J Thorac Cardiovasc Surg; 2003 Mar; 125(3):543-53. PubMed ID: 12658196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site.
    Seve P; Ray-Coquard I; Trillet-Lenoir V; Sawyer M; Hanson J; Broussolle C; Negrier S; Dumontet C; Mackey JR
    Cancer; 2006 Dec; 107(11):2698-705. PubMed ID: 17063500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy.
    Gautschi O; Bigosch C; Huegli B; Jermann M; Marx A; Chassé E; Ratschiller D; Weder W; Joerger M; Betticher DC; Stahel RA; Ziegler A
    J Clin Oncol; 2004 Oct; 22(20):4157-64. PubMed ID: 15483026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mental state as a possible independent prognostic variable for survival in patients with advanced lung carcinoma.
    Nakahara Y; Mochizuki Y; Miyamoto Y; Tanaka A; Kawamura T; Sasaki S; Nakahara Y; Katsura Y
    Cancer; 2002 Jun; 94(11):3006-15. PubMed ID: 12115391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic factors in lung cancer].
    Paesmans M
    Rev Mal Respir; 2005 Dec; 22(6 Pt 2):8S76-80. PubMed ID: 16340840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
    Nakashima J; Tachibana M; Horiguchi Y; Oya M; Ohigashi T; Asakura H; Murai M
    Clin Cancer Res; 2000 Jul; 6(7):2702-6. PubMed ID: 10914713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small-cell lung cancer.
    Zhu ZH; Sun BY; Ma Y; Shao JY; Long H; Zhang X; Fu JH; Zhang LJ; Su XD; Wu QL; Ling P; Chen M; Xie ZM; Hu Y; Rong TH
    J Clin Oncol; 2009 Mar; 27(7):1091-9. PubMed ID: 19188679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of tumor size in non-small cell lung cancer larger than five centimeters in diameter.
    Cangir AK; Kutlay H; Akal M; Güngör A; Ozdemir N; Akay H
    Lung Cancer; 2004 Dec; 46(3):325-31. PubMed ID: 15541817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer.
    Werle B; Kotzsch M; Lah TT; Kos J; Gabrijelcic-Geiger D; Spiess E; Schirren J; Ebert W; Fiehn W; Luther T; Magdolen V; Schmitt M; Harbeck N
    Anticancer Res; 2004; 24(6):4147-61. PubMed ID: 15736466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A lack of prognostic significance regarding DeltaNp63 immunoreactivity in lung cancer.
    Iwata T; Uramoto H; Sugio K; Fujino Y; Oyama T; Nakata S; Ono K; Morita M; Yasumoto K
    Lung Cancer; 2005 Oct; 50(1):67-73. PubMed ID: 15950316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.
    Asmis TR; Ding K; Seymour L; Shepherd FA; Leighl NB; Winton TL; Whitehead M; Spaans JN; Graham BC; Goss GD;
    J Clin Oncol; 2008 Jan; 26(1):54-9. PubMed ID: 18165640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.